الفهرس 
AcknowledgementOnly 14 pages are availabe for public view
 |  | from | 86 |  |  |
| | | from | 86 | | |
Abstract
Ulcer disease (PUD) embraces both gastric and duodenal ulcers. There r—i factors involved in the development of gastric and duodenal mucosal
as use of non-steroidal anti-inflammatory drugs (NSAIDs) and iv1ori infection. This disease had a tremendous effect on morbidity and
z::i the last decades of the 20th century. As a result of pharmacological and discovery of effective and potent acid suppressants as proton pump
zanagement of PUD has changed dramatically. Proton pump inhibitors as Omeprazole and Pantoprazole are widely used as first line acid They are extensively metabolized in the liver by cytochrome P450 ::stem. The principal enzyme involved in the metabolism is enzyme exhibits single nucleotide polymorphism.
are inter- individual differences in the activity of CYP2C 19 which in :he clinical outcomes of PPI-based PUD therapy. Two mutant alleles
- = and CYP2C19*3 were recently found responsible for genetically :bolic activity of CYP2C19. Therefore, in the current study the effect of zorphism of CYP2C19 on PUD therapy outcome has been investigated Egyptian patients. The study population included 91 PUD patients with between 18 and 70 years. Polymerase chain reaction—Restriction
un -ith polymorphism (PCR-RFLP) method was used to analyze the two ies CYP2C19*2, CYP2C19*3 and the wild type CYP2C19*1 gene in
:od samples of all patients. The current study confimed that most fast metabolizers and increasing PPIs dose twice daily would result in a
- zire rate for PUD patients.